haloperidol has been researched along with Injury, Ischemia-Reperfusion in 4 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A pilot dose-response study investigated an intracranial approach of topically applying endothelin-1 (ET-1) to the M2 portion of the middle cerebral artery in a small sample of marmosets for up to 6 hours (n = 2 or 3 per group)." | 5.32 | A new primate model of focal stroke: endothelin-1-induced middle cerebral artery occlusion and reperfusion in the common marmoset. ( David, C; Elliott, H; Farnfield, B; Golder, J; Hadingham, SJ; Hunter, AJ; Parsons, AA; Roberts, JC; Virley, D; Whelan, G, 2004) |
| " A pilot dose-response study investigated an intracranial approach of topically applying endothelin-1 (ET-1) to the M2 portion of the middle cerebral artery in a small sample of marmosets for up to 6 hours (n = 2 or 3 per group)." | 1.32 | A new primate model of focal stroke: endothelin-1-induced middle cerebral artery occlusion and reperfusion in the common marmoset. ( David, C; Elliott, H; Farnfield, B; Golder, J; Hadingham, SJ; Hunter, AJ; Parsons, AA; Roberts, JC; Virley, D; Whelan, G, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goyagi, T | 1 |
| Bhardwaj, A | 2 |
| Koehler, RC | 1 |
| Traystman, RJ | 2 |
| Hurn, PD | 2 |
| Kirsch, JR | 2 |
| Zhang, YM | 1 |
| Shi, GG | 1 |
| Tang, Z | 1 |
| Zheng, JH | 1 |
| Li, WQ | 1 |
| Guo, FX | 1 |
| Jia, QY | 1 |
| Harukuni, I | 1 |
| Shaivitz, AB | 1 |
| DeVries, AC | 1 |
| London, ED | 1 |
| Faraci, FM | 1 |
| Virley, D | 1 |
| Hadingham, SJ | 1 |
| Roberts, JC | 1 |
| Farnfield, B | 1 |
| Elliott, H | 1 |
| Whelan, G | 1 |
| Golder, J | 1 |
| David, C | 1 |
| Parsons, AA | 1 |
| Hunter, AJ | 1 |
4 other studies available for haloperidol and Injury, Ischemia-Reperfusion
| Article | Year |
|---|---|
Potent sigma 1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine provides ischemic neuroprotection without altering dopamine accumulation in vivo in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Blood Gas Analysis; Body Temperature; Brain Chemistry; Brai | 2003 |
Effects of N-n-butyl haloperidol iodide on myocardial ischemia/reperfusion injury and Egr-1 expression in rat.
Topics: Animals; Calcium; Creatine Kinase; Creatine Kinase, MB Form; Early Growth Response Protein 1; Halope | 2006 |
sigma(1)-receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine affords neuroprotection from focal ischemia with prolonged reperfusion.
Topics: Animals; Behavior, Animal; Brain Ischemia; Cerebral Infarction; Drug Administration Schedule; Halope | 2000 |
A new primate model of focal stroke: endothelin-1-induced middle cerebral artery occlusion and reperfusion in the common marmoset.
Topics: Animals; Behavior, Animal; Brain; Callithrix; Conditioning, Operant; Disease Models, Animal; Dose-Re | 2004 |